Case Highlights Polygenic Risk in Severe Hypertriglyceridemia

Share this content:
Case Highlights Polygenic Risk in Severe Hypertriglyceridemia
Case Highlights Polygenic Risk in Severe Hypertriglyceridemia

WEDNESDAY, July 26, 2017 (HealthDay News) -- Polygenic risk can mimic major monogenic mutation in severe hypertriglyceridemia, according to a case report published online July 25 in the Annals of Internal Medicine.

Priska Stahel, Ph.D., from the University of Toronto, and colleagues developed a score based on the 14 loci (28 alleles) that most affect triglyceride levels to examine whether a high polygenic risk for hypertriglyceridemia can mimic a major monogenic mutation. A 22-year-old male presented with severe hypertriglyceridemia despite overall excellent health, favorable lifestyle, and no other identifiable cause of the condition. In light of an extensive family history of cardiovascular disease, he underwent fasting plasma lipid testing, and the results revealed marked hypertriglyceridemia and markedly elevated total cholesterol levels. The patient had minimal alcohol intake and there was no evidence that diet was contributing to his lipid profile. He underwent gene sequencing of 69 genes most likely to explain his lipid profile.

The researchers identified no major mutations that are known to cause severe hypertriglyceridemia. The patient had E3/E2 APOE genotype, and no copy number variants were observed. Many common polymorphisms were identified that produced a triglyceride polygenic risk score of 19 (>99th percentile) and a low-density lipoprotein cholesterol polygenic risk score of 15 (92nd percentile).

"This case highlights the need for physicians to consider a polygenic cause for patients with severe hypertriglyceridemia," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »